Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism

Colorectal cancer (CRC) has a high mortality rate and poor prognosis. Despite chemotherapeutic agents such as cisplatin, which has achieved a better prognosis and survival rate against cancer, drug resistance leads to significant challenges. Accumulating evidence suggests that YTHDF1, the N(6)-methy...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ping, Liu, Xi-qiao, Lin, Xiang, Gao, Li-ying, Zhang, Shuo, Huang, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873577/
https://www.ncbi.nlm.nih.gov/pubmed/33614908
http://dx.doi.org/10.1016/j.omto.2021.01.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7873577/
https://www.ncbi.nlm.nih.gov/pubmed/33614908
http://dx.doi.org/10.1016/j.omto.2021.01.001

Ejemplares similares